Ian Weissman notes a voluntary recall of more than 3 million OTC eye-drop products after FDA findings on sterility assurance, underscoring manufacturing quality as a patient-safety and regulatory issue.
A pharmaceutical company has issued a voluntary recall of over 3 million of its over-the-counter eye-drop products after the FDA cited a lack of assurance of sterility.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare